Posted by SLS on February 27, 2012, at 21:57:09
In reply to Lou's request-fenfluramine, posted by Lou Pilder on February 27, 2012, at 20:28:57
> Now in relation to saphris, as to what the drug is and such, and what it can do to the taker of the drug, I would like to introduce in the expsition the drug known as {Fenfluramine}.
Okay.
> Now another drug called {phentermine} combined with (fenfluramine), gives a drug called Phen-fen.
> This drug has been taken off the marketAlso, fenfluramine itself has been taken off of the market.
> because of how it could cause heart disease and death.
Yes. Valvulopathy. Also, pulmonary hypertension if my memory serves me.
Fenfluramine is a dangerous drug.
> Now the drug Saphris activates in one way or another some of the same receptors as fenfluramine.
To the best of my knowledge, this is misinformation.
Fenfluramine is a serotonin releaser that activates many different serotonin (5-HT) receptors. Asenapine acivates only one serotonin receptor - 5-HT1a. The mechanism by which fenfluramine causes adverse heart effects is via 5-HT2b receptor activation. Saphris and fenfluramine are not alike in this respect.
> So if you read the Saphris PI there could be the disclosure of possible agranulosis.
To the best of my knowledge, agranulocytosis is not an adverse effect of Saphris.
Agranulocytosis is listed on the PI only because other drugs in its class have this side effect. Can you prove that a single case of agranulocyctosis has occurred with Saphris? I couldn't find a single case on Medline/Pubmed.
> In the clinical trials, there were many deaths.
To the best of my knowledge, this is misinformation.
Please provide citations for this statement.
Your use of the word "many" is an exagerration.
To the best of my knowledge the 3-post rule still applies. Life is good.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1011122
URL: http://www.dr-bob.org/babble/20120221/msgs/1011861.html